The cohort included 59 NSCLC patients with BRAF mutation (V600E, n = 43; Non-V600E, n = 16) and 358 NSCLC patients with WT BRAF. Their demographics and clinical feathers were similar, except for treatment lines (p = 0.01, Table 2). Here, BRAF is linked to non-small cell lung carcinoma.